Market Overview

BioAlliance Pharma Receives Approval to Begin ReLive Phase III Clinical Trial in Primary Liver Cancer in the US and Germany

Share:

BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company
dedicated to the development of orphan oncology and to…

Regulatory News:

BioAlliance Pharma SA (Euronext Paris - BIO), an innovative Company
dedicated to the development of orphan oncology and to supportive care
products, announces that it has received authorization to start its
Phase III ReLive clinical trial in primary liver cancer in the U.S. (IND
approval), following the review of the Livatag® development program by
the FDA, as well as in Germany after the German health agency green
light.

“The deployment strategy planned was to implement the clinical trial
first in France, then to expand it to Europe and then to the United
States in 2014. The schedule is currently fully respected as the study
is already implemented

See full press release

Posted-In: News Guidance Offerings Contracts FDA Management Global

 

Related Articles

View Comments and Join the Discussion!